大行评级丨瑞银：首予和誉“买入”评级及目标价25.2港元 看好公司的差异化管线

Core Viewpoint - UBS initiated coverage on Harmony Biosciences with a "Buy" rating and a target price of HKD 25.2, highlighting the company as an undervalued innovative oncology drug firm [1] Company Overview - Harmony has a robust pipeline with 12 clinical-stage assets and 10 disclosed preclinical candidates, indicating strong research and development capabilities [1] - The company entered a global licensing agreement with Merck for pimicotinib worth USD 605.5 million, showcasing its R&D potential [1] Financial Projections - UBS forecasts risk-adjusted peak sales for Harmony's core assets, pimicotinib and irpagratinib, at HKD 89 billion and HKD 48 billion, respectively, which exceed market expectations by 41% and 26% [1]